Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Intranasal Pretreatment with Z-Ligustilide, the Main Volatile Component of Rhizoma Chuanxiong, Confers Prophylaxis against Cerebral Ischemia via Nrf2 and HSP70 Signaling Pathways.

Authors: Li, Juan  Yu, Jie  Ma, Hui  Yang, Na  Li, Li  Zheng, Ding-Ding  Wu, Ming-Xia  Zhao, Zhi-Long  Qi, Hong-Yi 
Citation: Li J, etal., J Agric Food Chem. 2017 Mar 1;65(8):1533-1542. doi: 10.1021/acs.jafc.6b04979. Epub 2017 Feb 16.
Pubmed: (View Article at PubMed) PMID:28169530
DOI: Full-text: DOI:10.1021/acs.jafc.6b04979

Z-Ligustilide (Z-LIG) is a major component in Rhizoma Chuanxiong, which has been traditionally used as a health food supplement for the prevention of cerebrovascular disease in China. This study investigates the ability of intranasal Z-LIG pretreatment to enhance protection against neuronal damage in rats with middle cerebral artery occlusion (MCAO) and the role of cellular stress response mechanisms Nrf2 and HSP70. Z-LIG significantly mitigated infarct volume, neurological dysfunction, blood-brain barrier disruption, and brain edema (p < 0.01). Moreover, Z-LIG prevented the loss of collagen IV, occludin, and ZO-1 (p < 0.05) and decreased MMP-2 and -9 levels (p < 0.01). Meanwhile, Z-LIG up-regulated NQO1 and HSP70. Notably, blockage of Nrf2-driven transcription or down-regulation of HSP70 remarkably attenuated the preventive effect of Z-LIG (p < 0.05). Together, intranasal delivery of Z-LIG enhanced protection against ischemic injury via Nrf2 and HSP70 signaling pathways and has prophylactic potential in the population at high risk of stroke.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 13442499
Created: 2017-11-06
Species: All species
Last Modified: 2017-11-06
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.